These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 33207975)

  • 1. First trimester screening for aneuploidy: may combined test and fetal DNA work together?
    Capriglione S; Latella S; De Felice G; Filippini M; Ettore C; Ettore G; Farinelli M; Gulino FA
    J Matern Fetal Neonatal Med; 2022 Nov; 35(22):4258-4262. PubMed ID: 33207975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal reflex DNA screening for trisomies 21, 18, and 13.
    Wald NJ; Huttly WJ; Bestwick JP; Old R; Morris JK; Cheng R; Aquilina J; Peregrine E; Roberts D; Alfirevic Z
    Genet Med; 2018 Aug; 20(8):825-830. PubMed ID: 29120460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell-free DNA test contingent on results from first-trimester combined test.
    Gil MM; Revello R; Poon LC; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Jan; 47(1):45-52. PubMed ID: 26498918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.
    Audibert F; Gagnon A; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
    Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
    Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of combined detailed first-trimester ultrasound-biochemical analysis for screening fetal aneuploidy in the era of non-invasive prenatal testing.
    Ye C; Duan H; Liu M; Liu J; Xiang J; Yin Y; Zhou Q; Yang D; Yan R; Li R
    Arch Gynecol Obstet; 2024 Aug; 310(2):843-853. PubMed ID: 37938359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
    Kagan KO; Cicero S; Staboulidou I; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2009 Mar; 33(3):259-64. PubMed ID: 19248005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-trimester screening for trisomies 21 and 18.
    Wapner R; Thom E; Simpson JL; Pergament E; Silver R; Filkins K; Platt L; Mahoney M; Johnson A; Hogge WA; Wilson RD; Mohide P; Hershey D; Krantz D; Zachary J; Snijders R; Greene N; Sabbagha R; MacGregor S; Hill L; Gagnon A; Hallahan T; Jackson L;
    N Engl J Med; 2003 Oct; 349(15):1405-13. PubMed ID: 14534333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
    Spencer K; Nicolaides KH
    BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [What are the real purpose and scope of screening for aneuploidy?].
    Quibel T; Rozenberg P
    Gynecol Obstet Fertil Senol; 2018 Feb; 46(2):124-129. PubMed ID: 29396076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-trimester screening for trisomy 21 in Denmark: implications for detection and birth rates of trisomy 18 and trisomy 13.
    Ekelund CK; Petersen OB; Skibsted L; Kjaergaard S; Vogel I; Tabor A;
    Ultrasound Obstet Gynecol; 2011 Aug; 38(2):140-4. PubMed ID: 21229566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
    Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-trimester screening for trisomies in pregnancies with vanishing twin.
    Chaveeva P; Wright A; Syngelaki A; Konstantinidou L; Wright D; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Mar; 55(3):326-331. PubMed ID: 31710734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities.
    Kagan KO; Sonek J; Wagner P; Hoopmann M
    Arch Gynecol Obstet; 2017 Oct; 296(4):645-651. PubMed ID: 28702698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
    Dhaifalah I; Májek O
    Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.